Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Melanoma 19 Thyroid Neoplasms 6 Glioma 6 Thyroid Carcinoma, Anaplastic 5 Multiple Myeloma 5 Carcinoma, Non-Small-Cell Lung 5 Neoplasms 4 Neoplasm Metastasis 4 Colorectal Neoplasms 4 Thyroid Cancer, Papillary 3 Hematologic Neoplasms 3 Skin Neoplasms 2 Rectal Neoplasms 2 Ovarian Neoplasms 2 Lymphoma 2 Lung Neoplasms 2 Histiocytosis, Langerhans-Cell 2 Glioblastoma 2 Colonic Neoplasms 2 Brain Neoplasms 2 Astrocytoma 2 Adenocarcinoma, Follicular 2 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Thyroid cancer, follicular 1 Thyroid cancer, Hurthle cell 1 Stomach Neoplasms 1 Spinocerebellar Degenerations 1 Sarcoma 1

Interventions

Cyclophosphamide 51 fludarabine 37 Dexamethasone 35 venetoclax 30 pembrolizumab 25 Rituximab 20 pomalidomide 18 Lenalidomide 17 Gemcitabine 17 fludarabine phosphate 15 Etoposide 14 Cytarabine 13 daratumumab 12 carfilzomib 11 Temozolomide 11 Injections 10 Calcium Dobesilate 10 glofitamab 9 Nivolumab 9 Cisplatin 9 Bortezomib 9 Azacitidine 9 selinexor 8 Vincristine 8 Immunotherapy, Adoptive 8 obinutuzumab 7 cemiplimab 7 Drug Therapy 7 Carboplatin 7 zanubrutinib 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × dabrafenib × 1 year × Clear all

NCT06262919 2025-12-30

Special Drug Use-results Surveillance of Tafinlar/Mekinist

Novartis

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡